A Glycolysis-based Three-gene Signature Predicts Survival in Patients with Lung Squamous Cell Carcinoma

Overview

Journal BMC Cancer

Publisher Biomed Central

Specialty Oncology

Date 2021 May 28

PMID 34044809

Citations 6

Authors

Guichuan Huang

Jing Zhang

Ling Gong

Yi Huang

Daishun Liu

Affiliations

Soon will be listed here.

Abstract

Background: Lung cancer is one of the most lethal and most prevalent malignant tumors worldwide, and lung squamous cell carcinoma (LUSC) is one of the major histological subtypes. Although numerous biomarkers have been found to be associated with prognosis in LUSC, the prediction effect of a single gene biomarker is insufficient, especially for glycolysis-related genes. Therefore, we aimed to develop a novel glycolysis-related gene signature to predict survival in patients with LUSC.

Methods: The mRNA expression files and LUSC clinical information were obtained from The Cancer Genome Atlas (TCGA) dataset.

Results: Based on Gene Set Enrichment Analysis (GSEA), we found 5 glycolysis-related gene sets that were significantly enriched in LUSC tissues. Univariate and multivariate Cox proportional regression models were performed to choose prognostic-related gene signatures. Based on a Cox proportional regression model, a risk score for a three-gene signature (HKDC1, ALDH7A1, and MDH1) was established to divide patients into high-risk and low-risk subgroups. Multivariate Cox regression analysis indicated that the risk score for this three-gene signature can be used as an independent prognostic indicator in LUSC. Additionally, based on the cBioPortal database, the rate of genomic alterations in the HKDC1, ALDH7A1, and MDH1 genes were 1.9, 1.1, and 5% in LUSC patients, respectively.

Conclusion: A glycolysis-based three-gene signature could serve as a novel biomarker in predicting the prognosis of patients with LUSC and it also provides additional gene targets that can be used to cure LUSC patients.

Citing Articles

Energy metabolism as the hub of advanced non-small cell lung cancer management: a comprehensive view in the framework of predictive, preventive, and personalized medicine.

Bajinka O, Ouedraogo S, Golubnitschaja O, Li N, Zhan X EPMA J. 2024; 15(2):289-319.

PMID: 38841622 PMC: 11147999. DOI: 10.1007/s13167-024-00357-5.

A novel prognostic signature of coagulation-related genes leveraged by machine learning algorithms for lung squamous cell carcinoma.

Li G, He R, Huang Z, Huang H, Yang Z, Liu J Heliyon. 2024; 10(6):e27595.

PMID: 38496840 PMC: 10944263. DOI: 10.1016/j.heliyon.2024.e27595.

Exploration of spatial heterogeneity of tumor microenvironment in nasopharyngeal carcinoma via transcriptional digital spatial profiling.

Wang L, Wang D, Zeng X, Zhang Q, Wu H, Liu J Int J Biol Sci. 2023; 19(7):2256-2269.

PMID: 37151882 PMC: 10158028. DOI: 10.7150/ijbs.74653.

Determination of a prediction model for therapeutic response and prognosis based on chemokine signaling-related genes in stage I-III lung squamous cell carcinoma.

Lai J, Yang S, Chu S, Xu T, Huang J Front Genet. 2022; 13:921837.

PMID: 36118890 PMC: 9470854. DOI: 10.3389/fgene.2022.921837.

A Novel Small-Molecule Inhibitor of SREBP-1 Based on Natural Product Monomers Upregulates the Sensitivity of Lung Squamous Cell Carcinoma Cells to Antitumor Drugs.

Ma D, Liu X, Jia H, Zhang Y, Jiang Q, Sun H Front Pharmacol. 2022; 13:895744.

PMID: 35662712 PMC: 9157598. DOI: 10.3389/fphar.2022.895744.

References

Pirker R . What is the best strategy for targeting EGF receptors in non-small-cell lung cancer?. Future Oncol. 2015; 11(1):153-67. DOI: 10.2217/fon.14.178. View

Molinier O, Goupil F, Debieuvre D, Auliac J, Jeandeau S, Lacroix S . Five-year survival and prognostic factors according to histology in 6101 non-small-cell lung cancer patients. Respir Med Res. 2020; 77:46-54. DOI: 10.1016/j.resmer.2019.10.001. View

Wang X, Shi B, Zhao Y, Lu Q, Fei X, Lu C . HKDC1 promotes the tumorigenesis and glycolysis in lung adenocarcinoma via regulating AMPK/mTOR signaling pathway. Cancer Cell Int. 2020; 20:450. PMC: 7488676. DOI: 10.1186/s12935-020-01539-7. View

. Integrated genomic analyses of ovarian carcinoma. Nature. 2011; 474(7353):609-15. PMC: 3163504. DOI: 10.1038/nature10166. View

Marcato P, Dean C, Pan D, Araslanova R, Gillis M, Joshi M . Aldehyde dehydrogenase activity of breast cancer stem cells is primarily due to isoform ALDH1A3 and its expression is predictive of metastasis. Stem Cells. 2011; 29(1):32-45. DOI: 10.1002/stem.563. View

Zhang B, Tornmalm J, Widengren J, Vakifahmetoglu-Norberg H, Norberg E . Characterization of the Role of the Malate Dehydrogenases to Lung Tumor Cell Survival. J Cancer. 2017; 8(11):2088-2096. PMC: 5559971. DOI: 10.7150/jca.19373. View

Siegel R, Miller K, Jemal A . Cancer statistics, 2019. CA Cancer J Clin. 2019; 69(1):7-34. DOI: 10.3322/caac.21551. View

Giacalone N, Den R, Eisenberg R, Chen H, Olson S, Massion P . ALDH7A1 expression is associated with recurrence in patients with surgically resected non-small-cell lung carcinoma. Future Oncol. 2013; 9(5):737-45. PMC: 5341386. DOI: 10.2217/fon.13.19. View

Hanse E, Ruan C, Kachman M, Wang D, Lowman X, Kelekar A . Cytosolic malate dehydrogenase activity helps support glycolysis in actively proliferating cells and cancer. Oncogene. 2017; 36(27):3915-3924. PMC: 5501748. DOI: 10.1038/onc.2017.36. View

10.

Irwin D, Tan H . Molecular evolution of the vertebrate hexokinase gene family: Identification of a conserved fifth vertebrate hexokinase gene. Comp Biochem Physiol Part D Genomics Proteomics. 2010; 3(1):96-107. DOI: 10.1016/j.cbd.2007.11.002. View

11.

Chen X, Lv Y, Sun Y, Zhang H, Xie W, Zhong L . PGC1β Regulates Breast Tumor Growth and Metastasis by SREBP1-Mediated HKDC1 Expression. Front Oncol. 2019; 9:290. PMC: 6478765. DOI: 10.3389/fonc.2019.00290. View

12.

Zhang B, Xie Z, Li B . The clinicopathologic impacts and prognostic significance of GLUT1 expression in patients with lung cancer: A meta-analysis. Gene. 2018; 689:76-83. DOI: 10.1016/j.gene.2018.12.006. View

13.

Koppenol W, Bounds P, Dang C . Otto Warburg's contributions to current concepts of cancer metabolism. Nat Rev Cancer. 2011; 11(5):325-37. DOI: 10.1038/nrc3038. View

14.

Muzio G, Maggiora M, Paiuzzi E, Oraldi M, Canuto R . Aldehyde dehydrogenases and cell proliferation. Free Radic Biol Med. 2011; 52(4):735-46. DOI: 10.1016/j.freeradbiomed.2011.11.033. View

15.

Abbaszadeh Z, Cesmeli S, Biray Avci C . Crucial players in glycolysis: Cancer progress. Gene. 2019; 726:144158. DOI: 10.1016/j.gene.2019.144158. View

16.

Ge H, Yan Y, Wu D, Huang Y, Tian F . Potential role of LINC00996 in colorectal cancer: a study based on data mining and bioinformatics. Onco Targets Ther. 2018; 11:4845-4855. PMC: 6098418. DOI: 10.2147/OTT.S173225. View

17.

Osugi J, Yamaura T, Muto S, Okabe N, Matsumura Y, Hoshino M . Prognostic impact of the combination of glucose transporter 1 and ATP citrate lyase in node-negative patients with non-small lung cancer. Lung Cancer. 2015; 88(3):310-8. DOI: 10.1016/j.lungcan.2015.03.004. View

18.

Wang X, Li G, Luo Q, Xie J, Gan C . Integrated TCGA analysis implicates lncRNA CTB-193M12.5 as a prognostic factor in lung adenocarcinoma. Cancer Cell Int. 2018; 18:27. PMC: 5824544. DOI: 10.1186/s12935-018-0513-3. View

19.

Fu Q, Liu Y, Fan Y, Hua S, Qu H, Dong S . Alpha-enolase promotes cell glycolysis, growth, migration, and invasion in non-small cell lung cancer through FAK-mediated PI3K/AKT pathway. J Hematol Oncol. 2015; 8:22. PMC: 4359783. DOI: 10.1186/s13045-015-0117-5. View

20.

Feng J, Zhang X, Zhu H, Wang X, Ni S, Huang J . FoxQ1 overexpression influences poor prognosis in non-small cell lung cancer, associates with the phenomenon of EMT. PLoS One. 2012; 7(6):e39937. PMC: 3386178. DOI: 10.1371/journal.pone.0039937. View